Myostatin / activin pathway inhibitor

Taldefgrobep Alfa

A near-term obesity catalyst built around direct fat-mass and lean-mass endpoints.

Evidence Maturity · M2/M3 - Developing clinical Investigational - Phase 2b
Evidence reviewed: September 19, 2026Source-labeled

Signal summary

Taldefgrobep is valuable to RecompSignal not because its obesity efficacy is already established, but because the current trial asks exactly the questions our platform tracks.

Signal interpretation: This is a pure Pipeline Watch card. The value is being ready to update the page the moment the body-composition results arrive.

Study details

Doses studied — not a dosing recommendation. Regimens belong to the named study, formulation and population.

Registered phase 2b obesity trial

Population
Adults with overweight/obesity; estimated enrollment 150.
Doses and administration studied
Subcutaneous active/placebo arms once weekly or once every four weeks. Milligram doses are not disclosed in the reviewed registry entry.
Duration
Week 24 endpoints; estimated completion September 2026
Reported finding / status
Weight, fat and lean-mass outcomes are planned; no posted results in the reviewed record.
Interpretation and limitations
Estimated completion is not a promised results date. No established obesity dosing regimen can be inferred.

Source tier D · Read the original study or record

Outcome Evidence Strength

Weight change0/5
Fat-mass change0/5
Lean-mass change0/5
Strength / function benefit0/5

Awaiting obesity outcome results. Planned endpoints and mechanism do not earn efficacy evidence points.

Editorial evidence ratings for the cited outcomes, not effect size or treatment recommendations. A lean-mass score may describe loss. 0 means not established in the reviewed evidence, not proof of no effect. Read the rubric.

What is actually established?

  • The Phase 2b obesity trial is randomized, double-blind and placebo-controlled.
  • Its primary endpoint is percent change in total body weight at Week 24.
  • Secondary endpoints include percent change in total body fat mass and total body lean mass at Week 24.

What is not established?

  • No posted Phase 2b obesity results were available on the ClinicalTrials.gov record used for this card.
  • Until results are available, efficacy should not be inferred from mechanism or earlier sponsor statements.
  • Safety and function outcomes remain part of the developing evidence story.

Evidence sources

A = regulatory/official • B = peer-reviewed randomized/meta-analysis • C = peer-reviewed review/observational • D = registered trial • E = sponsor-reported • F = preclinical

Source tier D: Registered clinical trial
Taldefgrobep Alfa in Adults With Overweight and Obesity
Educational use only. This page summarizes research evidence and regulatory status. Study doses describe research, not prescribing instructions. This page does not provide personalized dosing, self-use protocols, sourcing, or a recommendation to use this therapy.